Skip to main content

Table 2 Change in IOP (mmHg) from baseline to week 4 (worse eye, ANCOVA, PP population)

From: A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension

  Latanoprost concentration (μg/mL)
  50 75 100 125
N 69 66 71 68
8 a.m. IOP
 LS mean change (mmHg)* −10.13 −9.59 −10.02 −9.06
 Adjusted difference in LS mean ± SEM   0.54 ± 0.46 0.12 ± 0.45 1.07 ± 0.45
 (90% CI)   (−0.22, 1.29) (−0.63, 0.86) (0.32, 1.82)
 p-value   0.879 0.602 0.990
4 p.m. IOP
 LS mean change (mmHg)* −8.90 −8.29 −8.81 −8.34
 Adjusted difference in LS mean ± SEM   0.60 ± 0.47 0.09 ± 0.45 0.55 ± 0.46
 (90% CI)   (−0.16, 1.37) (−0.67, 0.84) (−0.20, 1.31)
 p-value   0.902 0.575 0.885
  1. ANCOVA analysis of covariance, CI confidence interval, IOP intraocular pressure, LS least square, PP per protocol, SEM standard error of the mean.
  2. *Adjusting for baseline IOP (covariate) with dose group and center as factors.
  3. Higher concentration minus latanoprost 50 μg/mL; a negative difference in LS mean indicates that the higher concentration has a greater effect than latanoprost 50 μg/mL.
  4. One-sided p-value.